Tesamorelin

Both are GHRH analogues that stimulate endogenous GH release, but tesamorelin is more potent and longer-acting than sermorelin. Tesamorelin is FDA-approved as Egrifta and has 15+ years of clinical data showing robust visceral fat reduction and GH optimization. Sermorelin has a shorter half-life and requires more frequent dosing. Tesamorelin is considered more targeted and effective for body composition goals.

No — tesamorelin is fundamentally different from exogenous HGH. Tesamorelin stimulates YOUR body to release its own growth hormone naturally. It works WITH your pituitary gland’s feedback mechanisms. Exogenous HGH replaces your natural production, potentially suppressing your body’s own GH secretion over time. Tesamorelin preserves insulin sensitivity, whereas exogenous GH can reduce it. For most patients seeking GH optimization without disrupting natural feedback, tesamorelin is a more physiologic approach.

Tesamorelin is a peptide administered as a subcutaneous (under-the-skin) injection, typically once daily or as directed by your provider. Your kit includes sterile syringes, bacteriostatic water for reconstitution, and alcohol pads. Your provider will walk you through the injection technique during your initial consultation. Common injection sites are the abdomen, thigh, or upper arm — rotating sites helps prevent irritation.

Timeline varies by individual, but most patients experience: Week 1–2: Protocol established, injection technique mastered. Month 1: GH optimization begins, sleep quality improvements often noted. Month 2–3: Visible body composition changes, visceral fat reduction becomes measurable. Month 4–6: Full body recomposition effect, IGF-1 stabilization, sustained fat loss and muscle preservation. Clinical trials showed ~20% VAT reduction over the study period. Results depend on baseline body composition, diet, activity level, and adherence.

Tesamorelin (Egrifta) has 15+ years of clinical safety data in FDA-approved use for HIV-associated lipodystrophy, with many patients using it continuously. It works WITH your body’s natural GH feedback, so it does not cause the long-term suppression risks associated with exogenous HGH. That said, it is off-label for body composition optimization, so ongoing provider monitoring and periodic lab work are important to ensure continued safety and efficacy. Your provider will assess whether continued use is appropriate for your health goals.

Unlike exogenous HGH, which can reduce insulin sensitivity, tesamorelin preserves insulin sensitivity because it works through your body’s natural GH feedback loop. Clinical data shows tesamorelin does not negatively impact glucose control. However, if you have diabetes or prediabetes, your provider may recommend periodic glucose monitoring to track any changes. Always disclose your full metabolic health history during your initial consultation.